I-Mab Files Q3 2024 Investor Presentation
Ticker: NBP · Form: 6-K · Filed: Oct 24, 2024 · CIK: 1778016
Sentiment: neutral
Topics: investor-relations, presentation, quarterly-update
TL;DR
I-Mab dropped its Q3 investor deck - check it for pipeline updates and financials.
AI Summary
I-Mab, a biopharmaceutical company, filed a Form 6-K on October 24, 2024, to report its Q3 2024 investor presentation. The filing includes an investor presentation as Exhibit 99.1, detailing the company's progress and financial information for the third quarter of 2024.
Why It Matters
This filing provides investors with an update on I-Mab's performance and strategic direction for the third quarter of 2024, offering insights into its drug development pipeline and financial health.
Risk Assessment
Risk Level: low — This filing is a routine investor presentation and does not contain significant new material events or financial distress indicators.
Key Players & Entities
- I-Mab (company) — Filer of the Form 6-K
- October 24, 2024 (date) — Filing date and date of investor presentation
- 20241024 (date) — Conformed period of report and filed as of date
- 001-39173 (company) — SEC file number for I-Mab
- 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (address) — Principal executive offices and mailing address of I-Mab
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report an investor presentation for the third quarter of 2024, as indicated by Exhibit 99.1.
When was this filing submitted to the SEC?
This filing was submitted to the SEC on October 24, 2024.
What is the SEC file number associated with I-Mab?
The SEC file number associated with I-Mab is 001-39173.
What type of document is attached as Exhibit 99.1?
Exhibit 99.1 is an investor presentation dated October 24, 2024.
Where are I-Mab's principal executive offices located?
I-Mab's principal executive offices are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.
Filing Stats: 140 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-10-24 07:00:10
Filing Documents
- q32024_ir_presentation.htm (6-K) — 23KB
- imab-ex99_1.htm (EX-99.1) — 39KB
- imab-ex99_1s1.jpg (GRAPHIC) — 187KB
- imab-ex99_1s2.jpg (GRAPHIC) — 867KB
- imab-ex99_1s3.jpg (GRAPHIC) — 240KB
- imab-ex99_1s4.jpg (GRAPHIC) — 379KB
- imab-ex99_1s5.jpg (GRAPHIC) — 270KB
- imab-ex99_1s6.jpg (GRAPHIC) — 342KB
- imab-ex99_1s7.jpg (GRAPHIC) — 414KB
- imab-ex99_1s8.jpg (GRAPHIC) — 319KB
- imab-ex99_1s9.jpg (GRAPHIC) — 324KB
- imab-ex99_1s10.jpg (GRAPHIC) — 377KB
- imab-ex99_1s11.jpg (GRAPHIC) — 245KB
- imab-ex99_1s12.jpg (GRAPHIC) — 326KB
- imab-ex99_1s13.jpg (GRAPHIC) — 335KB
- imab-ex99_1s14.jpg (GRAPHIC) — 337KB
- imab-ex99_1s15.jpg (GRAPHIC) — 310KB
- imab-ex99_1s16.jpg (GRAPHIC) — 467KB
- imab-ex99_1s17.jpg (GRAPHIC) — 442KB
- imab-ex99_1s18.jpg (GRAPHIC) — 401KB
- imab-ex99_1s19.jpg (GRAPHIC) — 419KB
- imab-ex99_1s20.jpg (GRAPHIC) — 331KB
- imab-ex99_1s21.jpg (GRAPHIC) — 478KB
- imab-ex99_1s22.jpg (GRAPHIC) — 329KB
- imab-ex99_1s23.jpg (GRAPHIC) — 412KB
- imab-ex99_1s24.jpg (GRAPHIC) — 376KB
- imab-ex99_1s25.jpg (GRAPHIC) — 348KB
- imab-ex99_1s26.jpg (GRAPHIC) — 374KB
- imab-ex99_1s27.jpg (GRAPHIC) — 208KB
- 0000950170-24-116846.txt ( ) — 13634KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph Skelton Title : Chief Financial Officer Date: October 24, 2024